These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15196636)

  • 1. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough.
    Morilla MJ; Montanari JA; Prieto MJ; Lopez MO; Petray PB; Romero EL
    Int J Pharm; 2004 Jul; 278(2):311-8. PubMed ID: 15196636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?
    Morilla MJ; Prieto MJ; Romero EL
    Mem Inst Oswaldo Cruz; 2005 Apr; 100(2):213-9. PubMed ID: 16021311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
    Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
    Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease.
    Maximiano FP; de Paula LM; Figueiredo VP; de Andrade IM; Talvani A; Sá-Barreto LC; Bahia MT; Cunha-Filho MS
    Eur J Pharm Biopharm; 2011 Aug; 78(3):377-84. PubMed ID: 21397015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity.
    Morilla MJ; Montanari J; Frank F; Malchiodi E; Corral R; Petray P; Romero EL
    J Control Release; 2005 Apr; 103(3):599-607. PubMed ID: 15820407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
    Nogueira Silva JJ; Pavanelli WR; Gutierrez FR; Alves Lima FC; Ferreira da Silva AB; Santana Silva J; Wagner Franco D
    J Med Chem; 2008 Jul; 51(14):4104-14. PubMed ID: 18570370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
    Cencig S; Coltel N; Truyens C; Carlier Y
    Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.
    Fonseca-Berzal C; Palmeiro-Roldán R; Escario JA; Torrado S; Arán VJ; Torrado-Santiago S; Gómez-Barrio A
    Exp Parasitol; 2015 Feb; 149():84-91. PubMed ID: 25583295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.
    Francisco AF; de Abreu Vieira PM; Arantes JM; Pedrosa ML; Martins HR; Silva M; Veloso VM; de Lana M; Bahia MT; Tafuri WL; Carneiro CM
    Exp Parasitol; 2008 Dec; 120(4):314-9. PubMed ID: 18789321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.
    Magi MS; Lopez-Vidal L; García MC; Stempin CC; Marin C; Maletto B; Palma SD; Real JP; Jimenez-Kairuz AF
    Ther Deliv; 2024; 15(9):699-716. PubMed ID: 39101355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi.
    Pupulin AR; Marques-Araujo S; Toledo MJ; Gomes ML; Takejima E; Cuman RK; Bersani-Amado CA
    Exp Parasitol; 2010 Dec; 126(4):435-40. PubMed ID: 20433834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.
    Caldas S; Santos FM; de Lana M; Diniz LF; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Mar; 118(3):315-23. PubMed ID: 17945216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions.
    Figueirêdo CBM; Nadvorny D; Vieira ACQM; Schver GCRM; Soares Sobrinho JL; Rolim Neto PJ; Lee PI; Soares MFR
    Eur J Pharm Sci; 2018 Jul; 119():208-218. PubMed ID: 29679707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks.
    Leonardi D; Salomón CJ; Lamas MC; Olivieri AC
    Int J Pharm; 2009 Feb; 367(1-2):140-7. PubMed ID: 18938233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.
    Palmeiro-Roldán R; Fonseca-Berzal C; Gómez-Barrio A; Arán VJ; Escario JA; Torrado-Durán S; Torrado-Santiago S
    Int J Pharm; 2014 Sep; 472(1-2):110-7. PubMed ID: 24928135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.